Efficacy of Verapamil in patients with chronic rhinosinositis with nasal polyposis

Efficacy of Verapamil in patients with chronic rhinosinositis with nasal polyposis reffered to Hazrat Rasool hospital: Double blind placebo control trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191014045107N1

Enrollment

Registered

2019-12-09

Start date

2019-10-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis With polyoposis, Verapamil.

Interventions

Intervention 1: Intervention group: Receiving Verapamil Patients randomly are divided in 18 e

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients of Male And Female reffered to Allergy and Clinical Immunology Department of Hazrat e Rasool Center Age between 18-55 years old Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria; Moderate to Severe (Baseline SNOT-22 Score =20)

Exclusion criteria

Exclusion criteria: Patients with the following comorbidities: GI Hypomotility, Heart Failure, Liver Failure, Kidney Disease, Muscular Dystrophy, Pregnant or Nursing Females, Hypertrophic Cardiomyopathy, Atrial and ventricular arrhythmia Patients with conductive heart disease like block grade 2 or 3 in EKG Patients taking the following medications; Aspirin, Beta-blockers, Cimetidine, Clarithromycin, Erythromycin, Cyclosporin, Digoxin, Disopyramide, Diuretics, Flecainide, HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir), Quinidine, Lithium, Pioglitazone, Rifampin and systemic corticosteroids one month before trial HR<60 or SBP<110 or DBP<70

Design outcomes

Primary

Measure	Time frame
Efficacy of Verapamil in treatment of patients with CRSwNP based on SNOT-22 questionnaire score. Timepoint: SNOT-22 questionnaire completion in beginning and after 12 weeks of study. Method of measurement: SNOT-22 questionnaire validated in Farsi.	—

Secondary

Measure	Time frame
Efficacy of Verapamil in treatment of CRSwNP based on Lund - Mc Key score in sinonasal computer tomography scan. Timepoint: Measurement of LMS score in beginning and after 12 weeks of study. Method of measurement: Lund - Mc Key score in sinonasal computer tomography scan by 2 unrelated specialist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Nabavi

Iran University of Medical Sciences

mnabavi44@yahoo.com+98 21 6655 4933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026